-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HBV-IN-21
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2460957-52-0.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2460957-52-0 |
| Description | HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (KD = 60.0 μM). |
Product Information
| Synonyms | HBV-IN-21|HY-146011|CS-0460445 |
| Molecular Weight | 376.47 |
| Molecular Formula | C17H17FN4OS2 |
| Canonical SMILES | CC(C)CC1=C(N=C(S1)C2=NC=CS2)C(=O)NNC3=CC=C(C=C3)F |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 448 |
| Exact Mass | 376.08278169 |
| Target | IC50: 2.2 µM (HBV DNA replication) |
| XLogP3-AA | 4.9 |
